Clinical trial
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart…
NCT00284531 · Baylor College of Medicine, Other · Terminated
Key facts
| NCT number | NCT00284531 |
|---|---|
| Title | Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients |
| Official title | Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100 |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cardiac Transplantation |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 1 |
| Start date | Oct 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Feb 1, 2006 |
| Last update posted | Oct 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: